Kabra Drugs Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 271637,
    "name": "Kabra Drugs",
    "stock_name": "Kabra Drugs",
    "full_name": "Kabra Drugs Ltd",
    "name_url": "stocks-analysis/kabra-drugs",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "30.50",
    "chg": 0.59,
    "chgp": "1.97%",
    "dir": 1,
    "prev_price": "29.91",
    "mcapval": "72.31 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524322,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE323K01017",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": "11.7 k",
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/kabra-drugs-271637-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "How has been the historical performance of Kabra Drugs?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-kabra-drugs-3703266",
        "imagepath": "",
        "date": "2025-11-14 23:52:54",
        "description": "Answer:\nThe historical performance of Kabra Drugs shows a consistent lack of revenue generation, with net sales remaining at zero from March 2021 to March 2025, except for a nominal figure of 0.01 Cr in March 2019. The total operating income also reflects this trend, with minimal other operating income recorded in previous years. The company has incurred increasing total expenditures, rising from 0.05 Cr in March 2020 to 1.72 Cr in March 2025, primarily driven by employee costs and other expenses. Operating profit has been negative throughout this period, with losses deepening from -0.13 Cr in March 2019 to -1.08 Cr in March 2025. The profit before tax and profit after tax figures mirror this decline, showing losses that have increased over the years. On the balance sheet, shareholder's funds improved from -0.73 Cr in March 2023 to 24.65 Cr in March 2025, largely due to an increase in equity capital. Total ..."
      },
      {
        "title": "How has been the historical performance of Kabra Drugs?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-kabra-drugs-3699169",
        "imagepath": "",
        "date": "2025-11-13 23:25:50",
        "description": "Answer:\nThe historical performance of Kabra Drugs shows a consistent lack of revenue generation over the years, with net sales remaining at zero from March 2021 to March 2025, except for a nominal amount of 0.01 Cr in March 2019. The total operating income also reflects this trend, with only minor fluctuations in other operating income. The company's expenditures have increased significantly, particularly in employee costs, which rose from 0.03 Cr in March 2019 to 0.69 Cr in March 2025. This has led to a growing operating loss, with the operating profit (PBDIT) declining from -0.13 Cr in March 2019 to -1.08 Cr in March 2025. The profit before tax and profit after tax figures follow a similar pattern, indicating increasing losses over the years. The company's equity capital increased sharply to 23.71 Cr in March 2025 from 4.39 Cr in the previous years, and reserves improved to 0.95 Cr from negative values, s..."
      },
      {
        "title": "When is the next results date for Kabra Drugs?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-kabra-drugs-3681427",
        "imagepath": "",
        "date": "2025-11-07 23:22:02",
        "description": "The next results date for Kabra Drugs is scheduled for 13 November 2025...."
      },
      {
        "title": "How has been the historical performance of Kabra Drugs?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-kabra-drugs-3561266",
        "imagepath": "",
        "date": "2025-09-23 22:40:36",
        "description": "Answer:\nThe historical performance of Kabra Drugs shows a consistent lack of revenue generation, with net sales remaining at zero from March 2021 to March 2025, except for a nominal figure of 0.01 Cr in March 2019. The total operating income also reflects this trend, peaking at 0.02 Cr in March 2020 before declining to zero in subsequent years. The company's expenditures have increased significantly, with total expenditure rising from 0.14 Cr in March 2019 to 1.72 Cr in March 2025, primarily driven by escalating employee costs and other expenses. As a result, the operating profit has been negative, culminating in a loss of -1.08 Cr in March 2025. The profit before tax and profit after tax figures mirror this decline, with losses growing from -0.16 Cr in March 2019 to -1.09 Cr in March 2025. The company's equity capital has seen a substantial increase to 23.71 Cr in March 2025, up from 4.39 Cr in the previou..."
      },
      {
        "title": "Kabra Drugs Ltd Sees Strong Buying Activity Amidst Positive Short-Term Trends",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/kabra-drugs-ltd-gains-212-today-surpassing-sensex-amid-strong-buying-activity-3483615",
        "imagepath": "",
        "date": "2025-09-08 09:40:25",
        "description": "Kabra Drugs Ltd is currently witnessing significant buying activity, with the stock gaining 2.12% today, outperforming the Sensex, which rose by 0.38%. Over the past week, Kabra Drugs has shown a total increase of 3.12%, again surpassing the Sensex's 0.81% gain. Notably, the stock has experienced consecutive gains over the last two days, accumulating a total return of 7.24% during this period.\n\nIn terms of price performance, Kabra Drugs opened with a gap up and reached an intraday high, reflecting strong buyer sentiment. Despite a decline of 8.42% over the past month, the stock's performance over the longer term remains robust, with a remarkable 586.86% increase over the last five years compared to the Sensex's 111.18% rise.\n\nThe stock's current price is above its 5-day, 100-day, and 200-day moving averages, indicating a positive short-term trend, although it remains below the 20-day and 50-day moving avera..."
      }
    ],
    "total": 52,
    "sid": "271637",
    "stock_news_url": "https://www.marketsmojo.com/news/kabra-drugs-271637"
  },
  "announcements": [
    {
      "caption": "Submission Of Notice Of Extra Ordinary General Meeting Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligation And Disclosure Requirements) Regulations 2015",
      "datetime": "03-Dec-2025",
      "details": "Notice of Extra Ordinary General Meeting held on 26th December 2025 at Friday.",
      "source": "BSE"
    },
    {
      "caption": "Appointment Of Secretarial Auditor Of The Company",
      "datetime": "28-Nov-2025",
      "details": "Appointment of Secretarial Auditor of the Company",
      "source": "BSE"
    },
    {
      "caption": "Resignation Of Secretarial Auditor Of The Company",
      "datetime": "28-Nov-2025",
      "details": "Resignation of Secretarial Auditor of the Company",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

How has been the historical performance of Kabra Drugs?

2025-11-14 23:52:54

Answer: The historical performance of Kabra Drugs shows a consistent lack of revenue generation, with net sales remaining at zero from March 2021 to March 2025, except for a nominal figure of 0.01 Cr in March 2019. The total operating income also reflects this trend, with minimal other operating income recorded in previous years. The company has incurred increasing total expenditures, rising from 0.05 Cr in March 2020 to 1.72 Cr in March 2025, primarily driven by employee costs and other expenses. Operating profit has been negative throughout this period, with losses deepening from -0.13 Cr in March 2019 to -1.08 Cr in March 2025. The profit before tax and profit after tax figures mirror this decline, showing losses that have increased over the years. On the balance sheet, shareholder's funds improved from -0.73 Cr in March 2023 to 24.65 Cr in March 2025, largely due to an increase in equity capital. Total ...

How has been the historical performance of Kabra Drugs?

2025-11-13 23:25:50

Answer: The historical performance of Kabra Drugs shows a consistent lack of revenue generation over the years, with net sales remaining at zero from March 2021 to March 2025, except for a nominal amount of 0.01 Cr in March 2019. The total operating income also reflects this trend, with only minor fluctuations in other operating income. The company's expenditures have increased significantly, particularly in employee costs, which rose from 0.03 Cr in March 2019 to 0.69 Cr in March 2025. This has led to a growing operating loss, with the operating profit (PBDIT) declining from -0.13 Cr in March 2019 to -1.08 Cr in March 2025. The profit before tax and profit after tax figures follow a similar pattern, indicating increasing losses over the years. The company's equity capital increased sharply to 23.71 Cr in March 2025 from 4.39 Cr in the previous years, and reserves improved to 0.95 Cr from negative values, s...

When is the next results date for Kabra Drugs?

2025-11-07 23:22:02

The next results date for Kabra Drugs is scheduled for 13 November 2025....

How has been the historical performance of Kabra Drugs?

2025-09-23 22:40:36

Answer: The historical performance of Kabra Drugs shows a consistent lack of revenue generation, with net sales remaining at zero from March 2021 to March 2025, except for a nominal figure of 0.01 Cr in March 2019. The total operating income also reflects this trend, peaking at 0.02 Cr in March 2020 before declining to zero in subsequent years. The company's expenditures have increased significantly, with total expenditure rising from 0.14 Cr in March 2019 to 1.72 Cr in March 2025, primarily driven by escalating employee costs and other expenses. As a result, the operating profit has been negative, culminating in a loss of -1.08 Cr in March 2025. The profit before tax and profit after tax figures mirror this decline, with losses growing from -0.16 Cr in March 2019 to -1.09 Cr in March 2025. The company's equity capital has seen a substantial increase to 23.71 Cr in March 2025, up from 4.39 Cr in the previou...

Kabra Drugs Ltd Sees Strong Buying Activity Amidst Positive Short-Term Trends

2025-09-08 09:40:25

Kabra Drugs Ltd is currently witnessing significant buying activity, with the stock gaining 2.12% today, outperforming the Sensex, which rose by 0.38%. Over the past week, Kabra Drugs has shown a total increase of 3.12%, again surpassing the Sensex's 0.81% gain. Notably, the stock has experienced consecutive gains over the last two days, accumulating a total return of 7.24% during this period. In terms of price performance, Kabra Drugs opened with a gap up and reached an intraday high, reflecting strong buyer sentiment. Despite a decline of 8.42% over the past month, the stock's performance over the longer term remains robust, with a remarkable 586.86% increase over the last five years compared to the Sensex's 111.18% rise. The stock's current price is above its 5-day, 100-day, and 200-day moving averages, indicating a positive short-term trend, although it remains below the 20-day and 50-day moving avera...

View All News